NCT00944918 - Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Progression-free Survival

Interventions

DRUG

fulvestrant

Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.

DRUG

anastrozole

Tablet, oral, once daily until disease progression.

DRUG

exemestane

Tablet, oral, once daily until disease progression.

Trial Locations (2)

Research Site, Ilsan

Research Site, Seoul